Novartis AG (NVS)
USD 96.83
(-2.29%)
USD 96.83
(-2.29%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 18.28 Billion USD | 12.69% |
| 2022 | 14.72 Billion USD | -50.43% |
| 2021 | 17.13 Billion USD | 92.09% |
| 2020 | 15.23 Billion USD | 10.21% |
| 2019 | 15 Billion USD | -28.2% |
| 2018 | 14.13 Billion USD | 36.82% |
| 2017 | 13.9 Billion USD | 5.72% |
| 2016 | 13.19 Billion USD | 4.69% |
| 2015 | 14.36 Billion USD | -18.97% |
| 2014 | 17.65 Billion USD | 8.04% |
| 2013 | 15.89 Billion USD | -3.03% |
| 2012 | 16.92 Billion USD | -2.41% |
| 2011 | 17.09 Billion USD | 9.64% |
| 2010 | 15.81 Billion USD | 24.42% |
| 2009 | 12.77 Billion USD | 3.05% |
| 2008 | 12.45 Billion USD | 18.38% |
| 2007 | 10.58 Billion USD | -0.96% |
| 2006 | 10.18 Billion USD | 14.66% |
| 2005 | 8.78 Billion USD | 9.62% |
| 2004 | 7.97 Billion USD | 15.21% |
| 2003 | 7.26 Billion USD | 23.04% |
| 2002 | 5.9 Billion USD | 33.79% |
| 2001 | 4.41 Billion USD | -18.11% |
| 2000 | 5.62 Billion USD | 3.67% |
| 1999 | 5.55 Billion USD | -18.2% |
| 1998 | 6.35 Billion USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 5.61 Billion USD | 6.91% |
| 2024 Q1 | 4.94 Billion USD | 11.58% |
| 2024 Q2 | 5.09 Billion USD | 11.89% |
| 2023 Q4 | 4.18 Billion USD | -14.39% |
| 2023 FY | - USD | 12.69% |
| 2023 Q1 | 4.94 Billion USD | 26.59% |
| 2023 Q2 | 4.81 Billion USD | -2.61% |
| 2023 Q3 | 4.88 Billion USD | 1.39% |
| 2022 Q2 | 4.04 Billion USD | -5.36% |
| 2022 Q3 | 4.16 Billion USD | 2.82% |
| 2022 Q4 | 3.9 Billion USD | -6.06% |
| 2022 FY | - USD | -50.43% |
| 2022 Q1 | 4.27 Billion USD | -77.11% |
| 2021 Q2 | 5.15 Billion USD | 18.44% |
| 2021 Q4 | 18.67 Billion USD | 282.31% |
| 2021 FY | - USD | 92.09% |
| 2021 Q1 | 4.34 Billion USD | -0.64% |
| 2021 Q3 | 4.88 Billion USD | -5.16% |
| 2020 Q3 | 4.35 Billion USD | 3.37% |
| 2020 FY | - USD | 10.21% |
| 2020 Q1 | 4.27 Billion USD | 9.52% |
| 2020 Q4 | 4.37 Billion USD | 0.55% |
| 2020 Q2 | 4.21 Billion USD | -1.38% |
| 2019 Q4 | 3.89 Billion USD | -3.13% |
| 2019 Q1 | 3.8 Billion USD | 9.49% |
| 2019 Q3 | 4.02 Billion USD | 3.6% |
| 2019 FY | - USD | -28.2% |
| 2019 Q2 | 3.88 Billion USD | 2.05% |
| 2018 Q1 | 2.63 Billion USD | -37.8% |
| 2018 Q4 | 3.47 Billion USD | -9.57% |
| 2018 FY | - USD | 36.82% |
| 2018 Q3 | 3.84 Billion USD | -54.57% |
| 2018 Q2 | 8.46 Billion USD | 221.42% |
| 2017 Q3 | 4.11 Billion USD | 6.48% |
| 2017 FY | - USD | 5.72% |
| 2017 Q4 | 4.23 Billion USD | 2.97% |
| 2017 Q2 | 3.86 Billion USD | -1.08% |
| 2017 Q1 | 3.9 Billion USD | 26.8% |
| 2016 FY | - USD | 4.69% |
| 2016 Q4 | 3.07 Billion USD | -22.19% |
| 2016 Q3 | 3.95 Billion USD | 5.24% |
| 2016 Q2 | 3.75 Billion USD | -3.76% |
| 2016 Q1 | 3.9 Billion USD | 43.71% |
| 2015 Q2 | 3.82 Billion USD | -7.49% |
| 2015 Q1 | 4.13 Billion USD | -2.27% |
| 2015 FY | - USD | -18.97% |
| 2015 Q3 | 3.67 Billion USD | -3.94% |
| 2015 Q4 | 2.71 Billion USD | -26.1% |
| 2014 Q4 | 4.23 Billion USD | -13.23% |
| 2014 FY | - USD | 8.04% |
| 2014 Q3 | 4.88 Billion USD | 8.76% |
| 2014 Q2 | 4.48 Billion USD | -8.41% |
| 2014 Q1 | 4.9 Billion USD | 97.18% |
| 2013 Q4 | 2.48 Billion USD | -37.7% |
| 2013 Q3 | 3.98 Billion USD | -9.38% |
| 2013 FY | - USD | -3.03% |
| 2013 Q2 | 4.4 Billion USD | 4.61% |
| 2013 Q1 | 4.2 Billion USD | 4.86% |
| 2012 Q3 | 4.34 Billion USD | -4.78% |
| 2012 Q4 | 4.01 Billion USD | -7.53% |
| 2012 FY | - USD | -2.41% |
| 2012 Q1 | 4.08 Billion USD | 27.44% |
| 2012 Q2 | 4.55 Billion USD | 11.52% |
| 2011 Q4 | 3.2 Billion USD | -29.27% |
| 2011 FY | - USD | 9.64% |
| 2011 Q2 | 4.83 Billion USD | 1.75% |
| 2011 Q3 | 4.53 Billion USD | -6.23% |
| 2011 Q1 | 4.75 Billion USD | 40.93% |
| 2010 Q3 | 4.21 Billion USD | 11.08% |
| 2010 FY | - USD | 24.42% |
| 2010 Q1 | 4.42 Billion USD | 28.72% |
| 2010 Q2 | 3.79 Billion USD | -14.15% |
| 2010 Q4 | 3.37 Billion USD | -20.08% |
| 2009 Q3 | 3.27 Billion USD | 4.76% |
| 2009 Q1 | 2.93 Billion USD | -9.4% |
| 2009 Q2 | 3.12 Billion USD | 6.79% |
| 2009 Q4 | 3.43 Billion USD | 4.85% |
| 2009 FY | - USD | 3.05% |
| 2008 Q3 | 3.23 Billion USD | 24.28% |
| 2008 Q4 | 3.23 Billion USD | 0.12% |
| 2008 FY | - USD | 18.38% |
| 2008 Q2 | 2.59 Billion USD | -14.98% |
| 2008 Q1 | 3.05 Billion USD | 108.1% |
| 2007 Q4 | 1.46 Billion USD | -57.76% |
| 2007 Q2 | 2.46 Billion USD | -16.66% |
| 2007 Q1 | 2.95 Billion USD | 19.35% |
| 2007 FY | - USD | -0.96% |
| 2007 Q3 | 3.47 Billion USD | 41.27% |
| 2006 Q3 | 2.77 Billion USD | 5.19% |
| 2006 FY | - USD | 14.66% |
| 2006 Q2 | 2.64 Billion USD | 14.67% |
| 2006 Q4 | 2.47 Billion USD | -10.94% |
| 2006 Q1 | 2.3 Billion USD | -10.77% |
| 2005 FY | - USD | 9.62% |
| 2005 Q1 | 1.93 Billion USD | -2.67% |
| 2005 Q2 | 2.19 Billion USD | 13.45% |
| 2005 Q3 | 2.46 Billion USD | 12.18% |
| 2005 Q4 | 2.58 Billion USD | 4.96% |
| 2004 Q2 | 2.16 Billion USD | 21.9% |
| 2004 Q1 | 1.77 Billion USD | -2.37% |
| 2004 Q3 | 2.2 Billion USD | 2.04% |
| 2004 Q4 | 1.98 Billion USD | -9.89% |
| 2004 FY | - USD | 15.21% |
| 2003 Q1 | 1.65 Billion USD | 27.93% |
| 2003 Q3 | 1.83 Billion USD | 3.56% |
| 2003 FY | - USD | 23.04% |
| 2003 Q4 | 1.81 Billion USD | 0.55% |
| 2003 Q2 | 1.75 Billion USD | -8.31% |
| 2002 Q2 | 1.42 Billion USD | -70.65% |
| 2002 Q1 | 4.85 Billion USD | 149.55% |
| 2002 FY | - USD | 33.79% |
| 2002 Q4 | 1.88 Billion USD | 0.68% |
| 2002 Q3 | 1.48 Billion USD | 3.51% |
| 2001 Q1 | 4.44 Billion USD | 140.13% |
| 2001 FY | - USD | -18.11% |
| 2001 Q3 | 5.57 Billion USD | 486.95% |
| 2001 Q4 | -9.8 Billion USD | -275.84% |
| 2001 Q2 | 950 Million USD | -78.6% |
| 2000 FY | - USD | 3.67% |
| 2000 Q4 | -11.06 Billion USD | -326.7% |
| 2000 Q1 | 5.69 Billion USD | 0.0% |
| 2000 Q2 | 1 Billion USD | -72.13% |
| 2000 Q3 | 4.88 Billion USD | 207.37% |
| 1999 FY | - USD | -18.2% |
| 1998 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AbbVie Inc. | 26.35 Billion USD | 30.624% |
| Bristol-Myers Squibb Company | 19.41 Billion USD | 5.825% |
| Bristol-Myers Squibb Company Ce | 19.41 Billion USD | 5.825% |
| Johnson & Johnson | 23.72 Billion USD | 22.925% |
| Eli Lilly and Company | 8.56 Billion USD | -113.427% |
| Merck & Co., Inc. | 6.9 Billion USD | -164.746% |
| Organon & Co. | 1.43 Billion USD | -1173.398% |
| Pfizer Inc. | 9.55 Billion USD | -91.336% |